Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 4752.

https://doi.org/10.1182/blood-2019-122285

Published: 2019

Journal Articles

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Saskia K. Klein, MD PhD, Esther de Waal, PhD, Corien Eeltink, Charlotte L.B.M. Korst, MD, Paula F Ypma, MDPhD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD, Bea Tanis, PhD, Monique C Minnema, MD PhD, Henk M.W. Verheul, MD PhD, Birgit I. Lissenberg-Witte, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MD PhD, Sonja Zweegman, MD PhD

Blood (2018) 132 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2018-99-116920

Published: 2018

Journal Articles

Immunomodulatory Effects of Azacitidine Treatment In High Risk Myelodysplastic Syndrome

Hetty J Bontkes, Canan Alhan, Corien Eeltink, Theresia M. Westers, PhD, Gert J. Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2010) 116 (21): 1860.

https://doi.org/10.1182/blood.V116.21.1860.1860

Published: 2010

Journal Articles

Flow Cytometric Score Correlates with Clinical Response to Azacitidine In Intermediate-2 and High Risk Myelodysplastic Syndrome Patients

Canan Alhan, MD, Theresia M. Westers, PhD, Corien Eeltink, Claudia Cali, Gert J. Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2010) 116 (21): 441.

https://doi.org/10.1182/blood.V116.21.441.441

Published: 2010

Journal Articles

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Theresia M. Westers, Canan Alhan, Martine E. D. Chamuleau, Maurice J. D. L. van der Vorst, Corien Eeltink, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht

Blood (2010) 115 (9): 1779–1784.

https://doi.org/10.1182/blood-2009-08-239749

Published: 2010

Includes: Supplemental data

Journal Articles

Aberrant Phenotype of blasts in Low and Intermediate-1 Risk Myelodysplastic syndromes Predicts Response of Growth Factor Treatment. a Prospective clinical Phase-II Study.

Maurice JDL van der Vorst, MD, Theresia M Westers, PhD, Martine ED Chamuleau, MD, Corien Eeltink, Gert J Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2008) 112 (11): 1660.

https://doi.org/10.1182/blood.V112.11.1660.1660

Published: 2008

Journal Articles

T Cell Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Low and Intermediate-1 Risk Myelodysplastic Syndrome.

Martine E.D. Chamuleau, MD, Theresia M. Westers Ing, Linda van Dreunen, Judith Groenland, Adri Zevenbergen Ing, Corien Eeltink, Gert J. Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2007) 110 (11): 4603.

https://doi.org/10.1182/blood.V110.11.4603.4603

Published: 2007

NARROW

I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Immunomodulatory Effects of Azacitidine Treatment In High Risk Myelodysplastic Syndrome

Flow Cytometric Score Correlates with Clinical Response to Azacitidine In Intermediate-2 and High Risk Myelodysplastic Syndrome Patients

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Aberrant Phenotype of blasts in Low and Intermediate-1 Risk Myelodysplastic syndromes Predicts Response of Growth Factor Treatment. a Prospective clinical Phase-II Study.

T Cell Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Low and Intermediate-1 Risk Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Immunomodulatory Effects of Azacitidine Treatment In High Risk Myelodysplastic Syndrome

Flow Cytometric Score Correlates with Clinical Response to Azacitidine In Intermediate-2 and High Risk Myelodysplastic Syndrome Patients

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Aberrant Phenotype of blasts in Low and Intermediate-1 Risk Myelodysplastic syndromes Predicts Response of Growth Factor Treatment. a Prospective clinical Phase-II Study.

T Cell Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Low and Intermediate-1 Risk Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only